Single-agent vinorelbine in pretreated breast cancer patients: Comparison of two different schedules

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 2, 2004, Pages 207-213

  Terzoli, Edmondo ^a   Nistico C ^a   Fabi, A ^a   Milella, M ^a   Bria, E ^a   D'Ottavio, A M ^a   Vaccaro, A ^a   Vanni, B ^a   Garufi, C ^a   Ferraresi, V ^a   Giannarelli, D ^a   Papaldo, P ^a   Carlini, P ^a   Izzo, F ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Dose intensity; Vinorelbine

Indexed keywords

NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TIME FACTORS; VINBLASTINE;

EID: 3242711407     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Clark G.M., Sledge G.W. Jr., Osborne C.K. et al.: Survival from first recurrences: relative importance of prognostic factors in 1,015 breast cancer patients. J. Clin. Oncol. 1: 55-61, 1987
2. Holli K., Hakama M.: Treatment of the terminal stages of breast cancer. Br. Med. J. 298: 13-14, 1989.
3. Cold S., Jensen N.V., Brincker H. et al.: The influence of chemotherapy on survival after recurrence in breast cancer a 212 population-based study of patients treated in 1950s, 1960s and 1970s. Eur. J. Cancer 29A: 1146-1152, 1993.
4. Decker D.A., Ahmann D.L., Bisel H.F.: Complete responders to chemotherapy in metastatic breast cancer. JAMA 242: 2075-2079, 1979.
5. Nemoto T.: Metastatic breast cancer: prolonged complete response or possible cure by chemotherapy. Proc. Am. Soc. Clin. Oncol. 2: 110 (abs), 1983.
6. Hortobagyi G.N., Frye D.U., Buzdar A.U. et al.: Complete remissions in metastatic breast cancer: a thirteen year report. Proc. Am. Soc. Clin. Oncol. 7: 37 (abs), 1988.
7. Harris J.R., Morrow M., Norton L.: Malignant tumors of the breast. In: De Vita V T Jr, Hellman S, Rosenberg S A (eds), Cancer: Principles and Practice of Oncology. J B Lippincott: Philadelphia 1557-1616, 1997.
8. Romero A., Rabinovich M.G., Vallejo C.T. et al.: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J. Clin. Oncol. 12: 336-341, 1994.
9. Garcia-Conde J., Lluch A., Martin M., et al.: Phase II trial of weekly iv vinorelbine in first-line advanced breast cancer chemotherapy. Ann. Oncol. 5: 854-857, 1994.
10. Fumoleau P., Delgado F.M., Delazier T., et al.: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J. Clin. Oncol. 11: 1245-1252, 1993.
11. Weber B.L., Vogel C., Jones S., et al.: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J. Clin. Oncol. 13: 2722-2730, 1995.
12. Extra J.M., Leandri S., Dieras V., et al.: Phase II study of vinorelbine in first and second line treatment of advanced breast cancer. In: Pierre Fabre Oncologie eds.: Navelbine (vinorelbine) Update and New Trends. Solal Celigny, Von Libbey Eurotext publishers, Paris-London, 1991.
13. Tweeves C.J., Dobbs N.A., Curnow A. et al.: A phase II multicenter UK study of vinorelbine in advanced breast cancer. Br. J. Cancer 70: 990-993, 1994.
14. Gasparini G., Caffo O., Barni S. et al.: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J. Clin. Oncol. 12: 2094-2101, 1994.
15. Nisticò C., Garufi C., Miletta M. et al.: Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res. Treat. 59: 223-229, 2000.
16. Miller A., Hoogstraten B., Staquet M. et al.: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
17. Hryniuk W.M.: The importance of dose intensity in the outcome of chemotherapy. In: De Vita V T Jr, Hellman S, Rosenberg S A (eds), Important Advances in Oncology. Lippincott: Philadelphia, 1988, 121-142.
18. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 53: 475-481, 1958.
19. Johnson S.A., Harper P., Hortobagyi G.N. et al.: Vinorelbine: an overview. Cancer Treat. Rev. 22: 127-142, 1996.
20. Toussaint C., Izzo J., Spielmann M. et al.: Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J. Clin. Oncol. 12: 2102-2112, 1994.
21. Livingston R.B., Ellis C.K., Williams M.A. et al.: Dose-intensive vinorelbine with concurrent granulocyte colony stimulating factor support in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 15: 1395-1400, 1997.
22. Zelek L., Barthier S., Riofrio M. et al.: Weekly Vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92: 2267-2272, 2001.
23. Burstein H.J., Kuter I., Campos S.M. et al.: Clinical activity of Trastuzumab and Vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 19: 2722-2730, 2001.
24. Jahanzeb M., Mortimer J.E., Yunus F. et al.: Phase II trial of weekly vinorelbine and Trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. The Oncologist 7: 410-417, 2002.